Krista L Lanctôt1, Nathan Herrmann, Robert van Reekum, Goran Eryavec, Claudio A Naranjo. 1. Psychopharmacology Research Program and Geriatric Psychiatry, Sunnybrook and Women's College Health Sciences Centre, University of Toronto, 207s Bayview Avenue, Toronto, Ontario M4N 3M5, Canada. krista.lanctot@swchsc.on.ca
Abstract
BACKGROUND: Indications for serotonergic medications in the treatment of behavioral disorders associated with Alzheimer's disease (AD) remain to be established. METHOD:Sertraline (100 mg OD) was evaluated in a double-blind, randomized, placebo-controlled cross-over study in 22 nondepressed patients with severe probable AD and significant behavioral disturbance. Each subject was given a fenfluramine challenge to evaluate central serotonergic tone. RESULTS: Eight of 21 (38%) completers responded to sertraline. Drug responsive behaviors included aggression/agitation, irritability and aberrant motor behavior. Low aggression, female gender and large prolactin increase were associated with a better response. There was a trend for decreased aggression during sertraline versus placebo (p = 0.08). CONCLUSION:Aggression, gender and serotonergic function were associated with sertraline response. Larger randomized controlled trials are needed to clarify the profile of responders. Copyright 2002 John Wiley & Sons, Ltd.
RCT Entities:
BACKGROUND: Indications for serotonergic medications in the treatment of behavioral disorders associated with Alzheimer's disease (AD) remain to be established. METHOD:Sertraline (100 mg OD) was evaluated in a double-blind, randomized, placebo-controlled cross-over study in 22 nondepressed patients with severe probable AD and significant behavioral disturbance. Each subject was given a fenfluramine challenge to evaluate central serotonergic tone. RESULTS: Eight of 21 (38%) completers responded to sertraline. Drug responsive behaviors included aggression/agitation, irritability and aberrant motor behavior. Low aggression, female gender and large prolactin increase were associated with a better response. There was a trend for decreased aggression during sertraline versus placebo (p = 0.08). CONCLUSION:Aggression, gender and serotonergic function were associated with sertraline response. Larger randomized controlled trials are needed to clarify the profile of responders. Copyright 2002 John Wiley & Sons, Ltd.
Authors: Dilip V Jeste; Dan Blazer; Daniel Casey; Thomas Meeks; Carl Salzman; Lon Schneider; Pierre Tariot; Kristine Yaffe Journal: Neuropsychopharmacology Date: 2007-07-18 Impact factor: 7.853
Authors: Myuri T Ruthirakuhan; Nathan Herrmann; Damien Gallagher; Ana C Andreazza; Alexander Kiss; Nicolaas Paul L G Verhoeff; Sandra E Black; Krista L Lanctôt Journal: Contemp Clin Trials Commun Date: 2019-05-23
Authors: Myuri Ruthirakuhan; Nathan Herrmann; Ana C Andreazza; Nicolaas Paul L G Verhoeff; Damien Gallagher; Sandra E Black; Alex Kiss; Krista L Lanctôt Journal: J Alzheimers Dis Date: 2019 Impact factor: 4.472
Authors: Claudia Carrarini; Mirella Russo; Fedele Dono; Filomena Barbone; Marianna G Rispoli; Laura Ferri; Martina Di Pietro; Anna Digiovanni; Paola Ajdinaj; Rino Speranza; Alberto Granzotto; Valerio Frazzini; Astrid Thomas; Andrea Pilotto; Alessandro Padovani; Marco Onofrj; Stefano L Sensi; Laura Bonanni Journal: Front Neurol Date: 2021-04-16 Impact factor: 4.003